SynthesisBMC infectious diseases2025
Disease burden of norovirus-associated diarrhea among children under 5 years old in China: a meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveNorovirus (NoV) represents a major cause of acute diarrhea among children under 5 years old in China, yet its overall disease burden is frequently underestimated in systematic reporting. This meta-analysis aimed to provide a comprehensive assessment of the burden of NoV-related diarrhea in Chinese children under 5 years of age based on published literature between 2020 and 2024.
methodsWe conducted a systematic search across PubMed, Web of Science, CNKI, and WanFang Data, identifying 60 eligible studies. The quality of these studies was assessed using the STROBE checklist. Heterogeneity was evaluated through Cochran’s Q test and the I² statistic, while publication bias was examined using Egger’s test and funnel plots. Pooled positivity rates were analyzed employing a random-effects model. All analyses were done at 95% confidence interval (CI) and a p < 0.05 was considered significant.
resultsOnly one study provided incidence data, reporting a rate of 5,133.68 cases per 100,000 children. The overall pooled positivity rate of NoV among children under five was 15.76%, with the highest rate observed in the 1–3 years age group (21.29%). During the COVID-19 pandemic (2020–2021), the positivity rate declined to 15.74%; following the alleviating of containment measures, it rebounded rapidly to 20.75% in 2022–2023. followed by an increase to 20.75% in the 2022–2023 period. Seasonal increases were detected in spring (19.95%) and autumn (20.91%). Geographically, the highest positivity rate was found in Northwest China (17.24%). Genotype distribution revealed a predominance of GII strains (89.98%), with GII.4 Sydney (34.74%) and GII.4 Sydney [P31] (33.15%) being the most common variants.
conclusionThis study offers essential baseline information on the burden of NoV related diarrhea in China, underscoring the necessity for standardized incidence research, ongoing strain surveillance, and expedited vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.